Rifampicin (Synonyms: 利福平; Rifampin; Rifamycin AMP)

目录号: HY-B0272 纯度: 98.15%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Rifampicin 是一种有效的广谱抗生素，可抵抗细菌病原体。Rifampicin 具有抗流感病毒活性。Rifampicin 具有抗正痘活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Rifampicin Chemical Structure

CAS No. : 13292-46-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥530	In-stock
5 g	￥2092	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Rifampicin:

MCE 顾客使用本产品发表的 23 篇科研文献

: Rifampicin purchased from MCE. Usage Cited in: Phytomedicine. 2019 Mar 15;56:175-182. [Abstract]; Representative Western blots for P-gp、BCRP、MRP2 in LS-180 treated with six active compounds in liquorice. C: control, P-1: Rifampicin, P-2: Bosentan, S-1: Liquiritin, S-2: Liquiritigenin, S-3: Isoliquiritin, S-4: Isoliquiritigenin, S-5: Glycyrrhetinic acid, S-6: Licochalcone A.

: Rifampicin purchased from MCE. Usage Cited in: Onco Targets Ther. 2018 Sep 17;11:5885-5894. [Abstract]; MHCC97-H cells are treated with the indicated concentrations of Rifampicin for 48 hours. Then, cells are harvested for Western blot analysis.

Rifampicin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
A549	GI₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
A549	GI₅₀	> 100 μg/mL Compound: RP	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 27013391]
A549	GI₅₀	> 100 μg/mL Compound: RP	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 30910461]
A549	GI₅₀	> 100 μg/mL Compound: Rifampicin	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 28411559]
A549	GI₅₀	> 121.51 mM Compound: RP	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C6MD00278A
B-cell	IC₅₀	96 μM Compound: Rifampin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
CHO	CC₅₀	512 μM Compound: RIF	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
HCT-116	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
HCT-116	GI₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
HCT-116	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27914801]
HCT-116	CC₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27301367]
HCT-116	GI₅₀	> 121.51 mM Compound: RP	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	10.1039/C6MD00278A
HEK293	CC₅₀	> 100 μM Compound: Rifampicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay	[PMID: 30392371]
HEK293	IC₅₀	0.3 μM Compound: Rifampicin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate	[PMID: 22587986]
HEK293	EC₅₀	1.1 μM Compound: Rifampicin	Agonist activity at human PXR transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay Agonist activity at human PXR transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 26905831]
HEK293	IC₅₀	1.2 μM Compound: Rifampicin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	1.5 μM Compound: Rifampicin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	2.2 μM Compound: Rifampicin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate	[PMID: 22587986]
HEK293	IC₅₀	2.3 μM Compound: Rifampicin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate	[PMID: 22587986]
HEK293	IC₅₀	65 μM Compound: Rifampicin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HeLa	GI₅₀	> 100 μg/mL Compound: RP	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27013391]
HeLa	GI₅₀	> 100 μg/mL Compound: RP	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 30910461]
HeLa	GI₅₀	> 100 μg/mL Compound: Rifampicin	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 28411559]
HeLa	CC₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 27301367]
HeLa	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 26948407]
HeLa	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
HeLa	IC₅₀	270 μg/mL Compound: rifampin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
Hepatocyte	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against primary human hepatocytes assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against primary human hepatocytes assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
Hepatocyte	EC₅₀	0.98 μM Compound: Rifampicin	Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method	[PMID: 22815312]
Hepatocyte	EC₅₀	1.3 μM Compound: Rifampicin	Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method	[PMID: 22815312]
HepG2	EC₅₀	0.19 μM Compound: Rifampicin	Agonist activity at PXR expressed in human HepG2 cells after 24 hrs by p3A4-luciferase reporter gene assay Agonist activity at PXR expressed in human HepG2 cells after 24 hrs by p3A4-luciferase reporter gene assay	[PMID: 27145071]
HepG2	IC₅₀	145.33 μM Compound: Rifampicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 32249118]
HepG2	CC₅₀	175.9 μg/mL Compound: RIF	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33940463]
HepG2	IC₅₀	22.2 μM Compound: 75	Antimalarial activity against liver stages of Plasmodium yoelii 17XNL expressing GFP infected in human HepG2 cells transfected with CD81 assessed as growth inhibition of hepatic parasite after 40 hrs by flow cytometry Antimalarial activity against liver stages of Plasmodium yoelii 17XNL expressing GFP infected in human HepG2 cells transfected with CD81 assessed as growth inhibition of hepatic parasite after 40 hrs by flow cytometry	[PMID: 22122518]
HepG2	EC₅₀	3.2 μM Compound: Rifampicin	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	3.5 μM Compound: Rifampicin	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
Huh-7	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against human HuH7 cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 26948407]
Huh-7	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
J774.A1	IC₅₀	> 100 μM Compound: RIF	Cytotoxicity against mouse J774A1 cells assessed as cell viability after 24 hrs by Trypan blue exclusion assay Cytotoxicity against mouse J774A1 cells assessed as cell viability after 24 hrs by Trypan blue exclusion assay	[PMID: 24611928]
J774.A1	IC₅₀	> 64 μg/mL Compound: RFP	Cytotoxicity against mouse J774.A1 cells after 48 hrs by MTT assay Cytotoxicity against mouse J774.A1 cells after 48 hrs by MTT assay	[PMID: 36150342]
J774.A1	CC₅₀	207.03 μg/mL Compound: rifampin	Cytotoxicity against mouse J774A1 cells after 24 to 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 24 to 72 hrs by MTT assay	[PMID: 20934344]
Macrophage	IC₅₀	> 100 μM Compound: Rifampicin	Cytotoxicity against mouse bone marrow derived macrophage assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against mouse bone marrow derived macrophage assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 23454512]
MCF7	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
MCF7	GI₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
MCF7	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 27914801]
MCF7	GI₅₀	> 121.51 mM Compound: RP	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	10.1039/C6MD00278A
MDCK-II	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 26948407]
MDCK-II	IC₅₀	> 20 μM Compound: RIF	Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
MG-63	IC₅₀	240 μg/mL Compound: rifampin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MRC5	IC₅₀	> 100 μM Compound: Rifampicin	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method	[PMID: 26213786]
Osteoblast	IC₅₀	130 μg/mL Compound: rifampin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
PANC-1	GI₅₀	> 100 μg/mL Compound: RP	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 27013391]
PANC-1	GI₅₀	> 100 μg/mL Compound: RP	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 30910461]
PANC-1	GI₅₀	> 100 μg/mL Compound: Rifampicin	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 28411559]
PANC-1	CC₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human PANC1 cells by MTT assay Cytotoxicity against human PANC1 cells by MTT assay	[PMID: 27301367]
PBMC	IC₅₀	62.92 μg/mL Compound: RIF	Cytotoxicity against human PBMC assessed as reduction in cell growth after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell growth after 72 hrs by MTT assay	[PMID: 32977201]
RAW264.7	CC₅₀	80.39 μg/mL Compound: RIF	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33940463]
RAW264.7	GI₅₀	850 μM Compound: RIF	Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay	10.1039/C3MD00251A
THP-1	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
THP-1	GI₅₀	> 100 μg/mL Compound: RP	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 27013391]
THP-1	GI₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 27914801]
THP-1	CC₅₀	> 100 μg/mL Compound: Rifampicin	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 27301367]
THP-1	IC₅₀	> 100 μM Compound: Rifampicin	Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method	[PMID: 26213786]
THP-1	IC₅₀	0.0018 μg/mL Compound: Rifampicin	Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive dormant phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive dormant phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay	[PMID: 26299346]
THP-1	IC₅₀	0.0021 μg/mL Compound: Rifampicin	Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive active phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive active phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay	[PMID: 26299346]
THP-1	GI₅₀	0.14 μg/mL Compound: Rifampicin	Cytotoxicity against human THP1 cells assessed as growth inhibition by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition by MTT assay	[PMID: 28103537]
Vero	IC₅₀	> 10 μg/mL Compound: RIP	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as inhibition of cell viability after 96 hr by MTT assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as inhibition of cell viability after 96 hr by MTT assay	10.1007/s00044-012-0074-2
Vero	IC₅₀	> 100 μg/mL Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS-PMS assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS-PMS assay	[PMID: 24087924]
Vero	IC₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 20233660]
Vero	IC₅₀	> 100 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19058970]
Vero	IC₅₀	> 100 μg/mL Compound: RMP	Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 30891129]
Vero	IC₅₀	> 100 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 24 hrs by MTS assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 24 hrs by MTS assay	[PMID: 23454512]
Vero	IC₅₀	> 100 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 27426865]
Vero	IC₅₀	> 100 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells by MTS assay Cytotoxicity against African green monkey Vero cells by MTS assay	[PMID: 26748697]
Vero	IC₅₀	> 100 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay	[PMID: 29259747]
Vero	IC₅₀	> 100 μM Compound: Rifampin	Cytotoxicity against african green monkey Vero cells at < 10 uM after 3 days Cytotoxicity against african green monkey Vero cells at < 10 uM after 3 days	[PMID: 22850215]
Vero	CC₅₀	> 128 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay	[PMID: 31352245]
Vero	CC₅₀	> 150 μg/mL Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 26498570]
Vero	IC₅₀	> 200 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30145051]
Vero	CC₅₀	> 32 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31353295]
Vero	CC₅₀	> 50 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay	[PMID: 22691154]
Vero	IC₅₀	> 50 μM Compound: 52	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by tetrazolium dye assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by tetrazolium dye assay	[PMID: 28094223]
Vero	CC₅₀	> 500 μg/mL Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23062712]
Vero	IC₅₀	> 62.5 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24721315]
Vero	IC₅₀	> 62.5 μg/mL Compound: Rifampin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23352268]
Vero	IC₅₀	> 62.5 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 20056418]
Vero	IC₅₀	> 64 μg/mL Compound: RFP	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 36150342]
Vero	IC₅₀	> 64 μg/mL Compound: Rfp	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34126456]
Vero	IC₅₀	> 74.5 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero after 72 hrs by MTT assay	[PMID: 20576327]
Vero	CC₅₀	> 75.9 μM Compound: rifampicin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 72 hr by MTT assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 72 hr by MTT assay	10.1007/s00044-011-9638-9
Vero	IC₅₀	> 75.9 μM Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	CC₅₀	> 75.94 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 20615698]
Vero	IC₅₀	> 75.94 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19942326]
Vero	IC₅₀	> 75.94 μM Compound: rifampicin	Cytotoxicity against Vero cells after 72 hrs by MTT assay Cytotoxicity against Vero cells after 72 hrs by MTT assay	[PMID: 17276683]
Vero	IC₅₀	> 77.4 μM Compound: Rifampicin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr	10.1007/s00044-010-9322-5
Vero	IC₅₀	100 μg/mL Compound: rifampin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19926361]
Vero	IC₅₀	108 μM Compound: RMP, rifampicin	Cytotoxicity against african green monkey Vero cells by tetrazolium dye reduction assay Cytotoxicity against african green monkey Vero cells by tetrazolium dye reduction assay	[PMID: 24084159]
Vero	IC₅₀	113 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiter assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiter assay	[PMID: 22391032]
Vero	IC₅₀	113 μM Compound: rifampicin	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by CellTiter 96 assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by CellTiter 96 assay	[PMID: 24909079]
Vero	IC₅₀	113 μM Compound: RMP, RFC	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 21691438]
Vero	IC₅₀	122 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 20022500]
Vero	IC₅₀	122 μM Compound: 1	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 20000470]
Vero	IC₅₀	122 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 19863050]
Vero	IC₅₀	125 μM Compound: Rifampin	Cytotoxicity against african green monkey Vero cells by colorimetric assay Cytotoxicity against african green monkey Vero cells by colorimetric assay	[PMID: 20116900]
Vero	IC₅₀	127 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 19757815]
Vero	IC₅₀	127 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs by Cell titer assay Cytotoxicity against african green monkey Vero cells after 72 hrs by Cell titer assay	[PMID: 19271749]
Vero	IC₅₀	132.5 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay	[PMID: 24079882]
Vero	IC₅₀	137.6 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay	[PMID: 31951961]
Vero	IC₅₀	138.3 μM Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay	[PMID: 19119013]
Vero	CC₅₀	180 μM Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
Vero	CC₅₀	500 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28720502]
Vero	CC₅₀	500 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28646656]
Vero	CC₅₀	512 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
Vero	CC₅₀	512 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	CC₅₀	512 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29227930]
Vero	CC₅₀	512 μM Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30992202]
Vero	CC₅₀	512 μM Compound: RIF	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 30296686]
Vero	CC₅₀	7.8 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 29407980]
Vero	IC₅₀	97.4 μg/mL Compound: Rifampin	Cytotoxicity against African green monkey Vero cells by CellTiter 96 aqueous nonradioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 30295480]

体外研究
(In Vitro)

Rifampicin (100 μg/mL) 可阻断 P 糖蛋白的功能活性。Rifampicin 不是 P 糖蛋白的底物。Rifampicin 耐药性的机制与 P 糖蛋白的功能活性无关^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Rifampicin (200、400 mg/kg) 在高浓度下可诱发脂肪肝^[1]。Rifampicin (30 mg/kg，i.p.) 在体内处理 S464P 生物膜会导致其略微下降，但与原始信号相比，这些导管中的生物发光更早地重新结合，而 Rifampicin 对感染突变型 H481Y^[2] 的小鼠的生物发光没有影响。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

822.94

Formula

C₄₃H₅₈N₄O₁₂

CAS 号

13292-46-1

性状

固体

颜色

Pink to red

中文名称

利福平；利发霉素；甲哌利福霉素；甲哌力复霉素；威福仙；仙道伦；利米定

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 71.43 mg/mL (86.80 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2152 mL	6.0758 mL	12.1516 mL
5 mM	0.2430 mL	1.2152 mL	2.4303 mL
10 mM	0.1215 mL	0.6076 mL	1.2152 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (3.04 mM); 澄清溶液; 超声助溶

此方案可获得 2.5 mg/mL的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.04 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.15%

选择批次：

Data Sheet (643 KB) SDS (393 KB)

COA (269 KB) HNMR (329 KB) RP-HPLC (213 KB) MS (71 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. [Content Brief]

[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2. [Content Brief]

[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61. [Content Brief]

[4]. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74. [Content Brief]

[5]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Animal Administration ^[2]	Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifR mutants S464P or H481Y, are implanted subcutaneously in groups of nine mice per strain. One catheter segment is inserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group are treated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. The remaining four mice in each group are left untreated as controls. At various time points during the infection, the mice are anaesthetized using a constant flow of 1.5% isoflurane from the IVIS^® manifold, and imaged using an IVIS^® Image System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are analysed using LivingImage^® software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11 days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached by sonication for determination of bacterial burdens on the catheters. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. [Content Brief] [2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2. [Content Brief] [3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61. [Content Brief] [4]. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74. [Content Brief] [5]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Animal Administration
^[2]

Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifR mutants S464P or H481Y, are implanted subcutaneously in groups of nine mice per strain. One catheter segment is inserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group are treated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. The remaining four mice in each group are left untreated as controls. At various time points during the infection, the mice are anaesthetized using a constant flow of 1.5% isoflurane from the IVIS^® manifold, and imaged using an IVIS^® Image System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are analysed using LivingImage^® software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11 days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached by sonication for determination of bacterial burdens on the catheters.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. [Content Brief]

[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2. [Content Brief]

[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61. [Content Brief]

[4]. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74. [Content Brief]

[5]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Rifampicin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2152 mL	6.0758 mL	12.1516 mL	30.3789 mL
	5 mM	0.2430 mL	1.2152 mL	2.4303 mL	6.0758 mL
	10 mM	0.1215 mL	0.6076 mL	1.2152 mL	3.0379 mL
	15 mM	0.0810 mL	0.4051 mL	0.8101 mL	2.0253 mL
	20 mM	0.0608 mL	0.3038 mL	0.6076 mL	1.5189 mL
	25 mM	0.0486 mL	0.2430 mL	0.4861 mL	1.2152 mL
	30 mM	0.0405 mL	0.2025 mL	0.4051 mL	1.0126 mL
	40 mM	0.0304 mL	0.1519 mL	0.3038 mL	0.7595 mL
	50 mM	0.0243 mL	0.1215 mL	0.2430 mL	0.6076 mL
	60 mM	0.0203 mL	0.1013 mL	0.2025 mL	0.5063 mL
	80 mM	0.0152 mL	0.0759 mL	0.1519 mL	0.3797 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rifampicin13292-46-1Rifampin Rifamycin AMP利福平利发霉素甲哌利福霉素甲哌力复霉素威福仙仙道伦利米定BacterialInfluenza VirusAntibioticOrthopoxvirusInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Rifampicin (Synonyms: 利福平; Rifampin; Rifamycin AMP)

Customer Review

Other Forms of Rifampicin:

MCE 顾客使用本产品发表的 23 篇科研文献

Rifampicin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Rifampicin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Rifampicin (Synonyms: 利福平; Rifampin; Rifamycin AMP)

Customer Review

Other Forms of Rifampicin:

Rifampicin 相关抗体

MCE 顾客使用本产品发表的 23 篇科研文献

Rifampicin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Rifampicin 相关抗体:

摩尔计算器

稀释计算器

Rifampicin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z